No Carolina / NY / Florida
Ph: 561.316.3330

Lankenau Medical Center Performs the 1st Minimally Invasive Procedure for Aortic Regurgitation in the Philadelphia Region

Clinical trial establishes Lankenau as one of the most comprehensive heart valve centers nationally by offering yet another alternative to open-heart surgery

Summation

  • “We seek to treat our patients with the most effective, minimally invasive therapies available for their specific condition,” said Ramlawi, who also is co-director of the Lankenau Heart Institute and a professor for Lankenau Institute for Medical Research, which is Main Line Health's research division and oversees clinical trials.
  • Please remember the JenaValve ALIGN-AR is a research study and the use of these terms does not mean the use of the device has been found to be safe or effective for your condition.
  • A cardiac team led by Basel Ramlawi, MD, chief of cardiothoracic surgery at Main Line Health, conducted the procedure in May as part of the JenaValve ALIGN-AR trial using an experimental Trilogy™ heart valve system.

Lankenau Medical Center, part of Main Line Health, has performed the first minimally invasive catheter-based procedure to treat aortic regurgitation in the Philadelphia region.

A cardiac team led by Basel Ramlawi, MD, chief of cardiothoracic surgery at Main Line Health, conducted the procedure in May as part of the JenaValve ALIGN-AR trial using an experimental Trilogy™ heart valve system. The trial is the first use of a valve designed to treat aortic regurgitation through a minimally invasive procedure called transcatheter aortic valve replacement (TAVR).

Lankenau Medical Center has used TAVR to treat patients with aortic stenosis for over 10 years and was one of the first U.S. medical centers selected to offer it after the FDA approved the treatment option.

Aortic regurgitation is a condition where the aortic valve does not close tightly and allows blood to leak back into the heart’s main pumping chamber. The leakage may prevent the heart from operating efficiently to deliver blood to the rest of the body. Symptoms may include fatigue and shortness of breath and tend to develop gradually over months or years. The ALIGN-AR trial is for patients with symptomatic, severe aortic regurgitation who are at high risk for open surgery. The trial, among other Lankenau innovations, allows the Lankenau heart team to offer treatment strategies for complex valve disease in a patient-tailored approach.

“We seek to treat our patients with the most effective, minimally invasive therapies available for their specific condition,” said Ramlawi, who also is co-director of the Lankenau Heart Institute and a professor for Lankenau Institute for Medical Research, which is Main Line Health’s research division and oversees clinical trials. “We bring unique and distinct capabilities to this effort, with a decade of experience treating patients suffering from aortic stenosis using TAVR.”

Lankenau heart surgeons are national leaders in teaching minimally invasive and catheter-based valve procedures. Lankenau has performed more than 2,100 TAVR procedures for various conditions since 2012, including more than 300 in 2022. It is among the top 10% of highest performing TAVR centers in the nation.

The JenaValve Trilogy™ has been approved for commercial use in Europe but is not approved in the United States and is currently being investigated in the ALIGN-AR trial.

Lankenau continues to be a national leader in minimally invasive heart surgery. It performs the highest percentage of robotically assisted coronary bypass procedures in the country. It also is a leader in mitral valve repair using the MitraClipTM, a minimally invasive treatment for mitral valve regurgitation. The cardiac team performed its 300th MitraClip procedure last year.

This document uses words such as treatment, minimally invasive, and patient. Please remember the JenaValve ALIGN-AR is a research study and the use of these terms does not mean the use of the device has been found to be safe or effective for your condition.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

AscellaHealth CEO, Dea Belazi, Honored as a 2024 PM360 Elite 100 Winner

Dea Belazi said, "This honor truly belongs to the entire AscellaHealth team in recognition of their expertise, dedication and ongoing work that enables patients with complex, chronic conditions to access specialty pharmaceuticals and novel therapies that enhance clinical outcomes."

New Inflammatory Bowel Disease Center Opens at Northwell Health

The new Inflammatory Bowel Disease Center, located at 125 Community Drive in Manhasset, has 13 exam rooms, two procedural rooms and six infusion bays. Since it started operations, people have travelled from all over the country – and as far away as Alaska – to receive high-quality care.

Cold Spring Harbor Laboratory and Northwell Health Extend Strategic Affiliation

“The alliance between Cold Spring Harbor Laboratory (CSHL) and Northwell Health brings transformative bioscience research into the clinic,” says CSHL President & CEO Bruce Stillman. “As New York’s largest healthcare provider, Northwell Health serves a remarkably diverse patient population. This agreement will provide patient communities with greater access to cutting-edge biomedical technology, allowing for more precise diagnoses and treatments, and ultimately facilitating new breakthroughs in cancer care.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy